Subject(s)
Humans , Male , Child , Equatorial Guinea/ethnology , Splenomegaly/diagnosis , Splenomegaly/pathology , Splenomegaly/therapy , Equatorial Guinea/epidemiology , Splenomegaly/blood , Splenomegaly/complications , Splenomegaly/ethnology , Splenomegaly/epidemiology , Splenomegaly/etiology , SplenomegalySubject(s)
Malaria , Splenomegaly/parasitology , Child , Equatorial Guinea , Humans , Malaria/immunology , Male , Splenomegaly/immunologyABSTRACT
El objetivo de este trabajo ha sido comparar dos pautas de tratamiento con dexametasona en el tratamiento de la meningitis neumocócica: una pauta corta de 48h y una larga de 96h. Estudio retrospectivo en el que se comparan dos pautas de tratamiento con dexametasona en una serie de 18 casos de meningitis neumocócica. Se observa una mayor duración de la fiebre primaria en el grupo que recibe la pauta corta de dexametasona estadísticamente significativa sin diferencias en cuanto al desarrollo de fiebre secundaria y en la evolución a muerte y/o secuelas neurológicas graves. Se concluye que no existen diferencias importantes entre las dos pautas de tratamiento y en la necesidad de desarrollar marcadores de mala evolución y nuevos tratamientos adyuvantes para mejorar el pronóstico de la enfermedad (AU)
Our aim was two compare two different dexamethasone administration schedules in pneumococcal meningitis: short course (48h) and long course (96h) treatment. We diagnosed 18 pneumococcal meningitis treated with the two different schedules. We found a statistically significant longer duration of primary fever in patients who received dexamethasone for two days. We found no differences in the appearance of secondary fever, or in the development of severe neurological handicaps, or death between the two groups. We conclude that they are no significant differences between the two treatment schedules and that there is a need for developing early prognostic markers and adjuvant therapies that improve the outcome of patients with pneumococcal meningitis (AU)
Subject(s)
Humans , /drug therapy , Dexamethasone/administration & dosage , Retrospective Studies , Fever/epidemiology , Chemotherapy, Adjuvant , Pneumococcal Infections/drug therapyABSTRACT
Our aim was two compare two different dexamethasone administration schedules in pneumococcal meningitis: short course (48h) and long course (96h) treatment. We diagnosed 18 pneumococcal meningitis treated with the two different schedules. We found a statistically significant longer duration of primary fever in patients who received dexamethasone for two days. We found no differences in the appearance of secondary fever, or in the development of severe neurological handicaps, or death between the two groups. We conclude that they are no significant differences between the two treatment schedules and that there is a need for developing early prognostic markers and adjuvant therapies that improve the outcome of patients with pneumococcal meningitis.
Subject(s)
Anti-Inflammatory Agents/administration & dosage , Dexamethasone/administration & dosage , Meningitis, Pneumococcal/drug therapy , Child , Child, Preschool , Drug Administration Schedule , Female , Humans , Infant , Male , Retrospective StudiesSubject(s)
Humans , Male , Child, Preschool , Sarcoidosis/diagnosis , Parotid Diseases/etiology , Diagnosis, DifferentialABSTRACT
El Staphylococcus aureus resistente a la meticilina adquirido en la comunidad (SARM-AC) es actualmente un microorganismo emergente en todo el mundo, que puede producir infecciones cutáneas y de partes blandas, algunas de éstas graves, como la fascitis necrosante, además de neumonía y osteomielitis. A continuación se presenta un caso de fascitis necrosante en un niño de 14 meses de edad, que se confirmó mediante resonancia magnética, producido por SARM-AC productor de leucocidina de Panton-Valentine. La evolución clínica fue buena después del tratamiento quirúrgico precoz y de la administración de clindamicina por vía intravenosa durante 2 semanas. En este trabajo se revisan los aspectos microbiológicos y las pautas de tratamiento de estas infecciones (AU)
Community-Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) is a worldwide emerging pathogen that is able to produce serious skin and soft- tissue infections such as necrotizing fasciitis, as well as pneumonia and osteomyelitis. We present a 14 month child with necrotizing fasciitis, confirmed by magnetic resonance imaging, produced by CA-MRSA Panton-Valentine leukocidin producer. The clinical outcome was good after early surgical treatment and the administration of intravenous clindamycin for two weeks. We review microbiological aspects and treatment guidelines of these infections (AU)
Subject(s)
Humans , Male , Infant , Fasciitis, Necrotizing/pathology , Staphylococcus aureus/pathogenicity , Methicillin Resistance , Community-Acquired Infections/epidemiology , Penicillin-Binding Proteins/immunology , Bacterial Toxins/immunology , Bacterial Toxins/toxicity , Anti-Bacterial Agents/therapeutic use , Magnetic Resonance Imaging/methods , Magnetic Resonance Imaging , Mupirocin/pharmacologyABSTRACT
Community-Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) is a worldwide emerging pathogen that is able to produce serious skin and soft- tissue infections such as necrotizing fasciitis, as well as pneumonia and osteomyelitis. We present a 14 month child with necrotizing fasciitis, confirmed by magnetic resonance imaging, produced by CA-MRSA Panton-Valentine leukocidin producer. The clinical outcome was good after early surgical treatment and the administration of intravenous clindamycin for two weeks. We review microbiological aspects and treatment guidelines of these infections.
Subject(s)
Bacterial Toxins/biosynthesis , Exotoxins/biosynthesis , Fasciitis, Necrotizing/microbiology , Leukocidins/biosynthesis , Methicillin-Resistant Staphylococcus aureus/metabolism , Staphylococcal Infections , Community-Acquired Infections , Humans , Infant , MaleABSTRACT
No disponible
